Compare CAPR & HIVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPR | HIVE |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 447.1M |
| IPO Year | 2011 | 2017 |
| Metric | CAPR | HIVE |
|---|---|---|
| Price | $7.60 | $1.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $27.25 | $5.17 |
| AVG Volume (30 Days) | 4.2M | ★ 10.2M |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $297,791,000.00 |
| Revenue This Year | N/A | $18.39 |
| Revenue Next Year | $85.77 | $41.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 158.32 |
| 52 Week Low | $2.96 | $1.34 |
| 52 Week High | $40.37 | $5.34 |
| Indicator | CAPR | HIVE |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 22.34 |
| Support Level | $7.78 | N/A |
| Resistance Level | $10.62 | $2.33 |
| Average True Range (ATR) | 1.18 | 0.13 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 19.61 | 1.37 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
HIVE Digital Technologies Ltd is a sustainable-energy-focused digital infrastructure company that provides infrastructure solutions through the operation of Tier-1 and Tier-3 data centers. Its computing power is used for high-performance computing (HPC) and for generating hashrate sold to mining pools for cryptocurrency mining. The Company uses cash flow from its hashrate services business to support the expansion of its AI and HPC operations through its subsidiary. The Company focuses on Canada, Sweden, and Paraguay, where low-cost renewable power supports its operations and expansion. It operates in one segment with two revenue streams: the mining and sale of digital currencies and high-performance computing hosting. The majority of its revenue is generated from Bermuda.